This expanded plasma ATI(N) system, in combination with APOE genotyping and cognitive testing, presents an opportunity for personalized assessment, enabling a therapy approach tailored to the specific biomarker profiles of patients with AD. This evidence concerns the gene APOE and Alzheimer disease.